Key result
ACE inhibitors prevent new onset diabetes and reduce the risk of diabetic complications by blocking the renin-angiotensin system.
Why the study?
Do ACE inhibitors prevent new onset diabetes and reduce diabetic complications in patients with or at risk for diabetes?
Do ACE inhibitors prevent new onset diabetes and reduce diabetic complications in patients with or at risk for diabetes?
This review highlights the clinical evidence supporting the use of ACE inhibitors to prevent new onset diabetes and reduce diabetic complications.
Supports ACE inhibitor consideration for diabetes prevention; leaves open need for confirmatory randomized trials.
Angiotensin-converting enzyme (ACE) inhibitors have been FDA-approved for treating refractory hypertension since 1981. Since then, clinical investigations support the benefits of ACE inhibition (ACE-I) in pathologies like congestive heart failure, myocardial infarction, diabetes mellitus, chronic renal insufficiency, and atherosclerotic cardiovascular disease. Both, clinical trials and animal models of type I and type II diabetes have shown that hyperactivity of the angiotensin II signaling pathway contributes to the development of diabetes and its complications, and that blockade of the renin-angiotensin system prevents new onset diabetes and reduces the risk of diabetic complications. Furthermore, ACE inhibitors are generally well tolerated and have few contraindications. This article describes ACE as a target molecule and gives an overview on the clinical evidence that supports the use of ACE inhibitors in diabetes.
No takes yet. Share an insight, caveat, or question.
Ramos‐Niño et al. (2009) conducted a review in Diabetes. ACE inhibitors was evaluated. ACE inhibitors prevent new onset diabetes and reduce the risk of diabetic complications by blocking the renin-angiotensin system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: